Osseon Therapeutics has announced that it has named Ron Clough as chief operating officer.
Clough has extensive experience with several companies that develop and market medical devices for the treatment of spinal disease and deformities. Most recently, he served as VP of Operations at Theken Spine and was a key executive in the acquisition and integration of Theken Spine into Integra LifeSciences. Integra LifeSciences acquired Theken for US$200 million dollars in a two-year earn out in July 2008.
“Osseon has a terrific opportunity to focus on the customer in the VCF marketplace. We plan to leverage the depth of expertise within our employees to the benefit of patients, physicians, and distributors in our arena,” said Clough.
“Osseon is very excited that Clough has joined the management team. He brings unparalleled experience and expertise in the spinal device market,” said John Stalcup, president, Osseon.